The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions

Simple item page
dc.contributor.authorCarr, Robert
dc.contributor.authorOzdag, Hilal
dc.contributor.authorTekin, Nilgun
dc.contributor.authorMorris, Timothy
dc.contributor.authorConget, Paulette
dc.contributor.authorBruna, Flavia
dc.contributor.authorTimar, Botond
dc.contributor.authorGagyi, Eva
dc.contributor.authorBasak, Ranjan
dc.contributor.authorNaik, Omkar
dc.contributor.authorAuewarakul, Chirayu
dc.contributor.authorSrithana, Narongrit
dc.contributor.authorDimamay, Mark Pierre
dc.contributor.authorNatividad, Filipinas
dc.contributor.authorChung, June-Key
dc.contributor.authorBelder, Nevin
dc.contributor.authorKuzu, Isinsu
dc.contributor.authorOmidvar, Nader
dc.contributor.authorPaez, Diana
dc.contributor.authorPadua, Rose Ann
dc.date.accessioned2017-08-11T13:23:34Z
dc.date.available2017-08-11T13:23:34Z
dc.date.issued2016
dc.description.abstractAddressing the global burden of cancer, understanding its diverse biology, and promoting appropriate prevention and treatment strategies around the world has become a priority for the United Nations and International Atomic Energy Agency (IAEA), the WHO, and International Agency for Research on Cancer (IARC). The IAEA sponsored an international prospective cohort study to better understand biology, treatment response, and outcomes of diffuse large B-cell lymphoma (DLBCL) in low and middle-income countries across five UN-defined geographical regions. We report an analysis of biological variation in DLBCL across seven ethnic and environmentally diverse populations. In this cohort of 136 patients treated to a common protocol, we demonstrate significant biological differences between countries, characterized by a validated prognostic gene expression score (pā€‰<ā€‰.0001), but International Prognostic Index (IPI)-adjusted survivals in all participating countries were similar. We conclude that DLBCL treatment outcomes in these populations can be benchmarked to international standards, despite biological heterogeneity.
dc.description.versionVersiĆ³n enviada
dc.format.extent6
dc.identifier.citationCarr R, Ozdag H, Tekin N, Morris T, Conget P, Bruna F, Timar B, Gagyi E, Basak R, Naik O, Auewarakul C, Srithana N, Dimamay MP, Natividad F, Chung JK, Belder N, Kuzu I, Omidvar N, Paez D, Padua RA. The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions. Leuk Lymphoma. 2017 May;58(5):1178-1183. doi: 10.1080/10428194.2016.1231308
dc.identifier.urihttp://hdl.handle.net/11447/1564
dc.identifier.urihttp://dx.doi.org/10.1080/10428194.2016.1231308
dc.language.isoen_US
dc.publisherTaylor & Francis Online
dc.sourceLeukemia & Lymphoma
dc.subjectDLBCL
dc.subjectgene expression
dc.subjectprognosis
dc.subjectrisk stratification
dc.titleThe effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions
dc.typeArtĆ­culo

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions.pdf
Size:
322.14 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download

Collections

ArtĆ­culos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services